Maintenance DFMO Increases Survival in High Risk Neuroblastoma-Reference-Cited by-同舟云学术

Maintenance DFMO Increases Survival in High Risk Neuroblastoma

Published:2018-09-27 Issue:1 Volume:8 Page:
ISSN:2045-2322
Container-title:Scientific Reports
language:en
Short-container-title:Sci Rep

Author:

Sholler Giselle L. Saulnier,Ferguson William,Bergendahl Genevieve,Bond Jeffrey P.,Neville Kathleen,Eslin Don,Brown Valerie,Roberts William,Wada Randal K.,Oesterheld Javier,Mitchell Deanna,Foley Jessica,Parikh Nehal S.,Eshun Francis,Zage Peter,Rawwas Jawhar,Sencer Susan,Pankiewicz Debra,Quinn Monique,Rich Maria,Junewick Joseph,Kraveka Jacqueline M.

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/s41598-018-32659-w.pdf

Reference33 articles.

1. Irwin, M. S. & Park, J. R. Neuroblastoma: paradigm for precision medicine. Pediatric clinics of North America 62, 225–256, https://doi.org/10.1016/j.pcl.2014.09.015 (2015).

2. Pinto, N. R. et al. Advances in Risk Classification and Treatment Strategies for Neuroblastoma. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 33, 3008–3017, https://doi.org/10.1200/JCO.2014.59.4648 (2015).

3. Simon, T. et al. Consolidation treatment with chimeric anti-GD2-antibodych14.18 in children older than 1 year with metastatic neuroblastoma. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 22, 3549–3557, https://doi.org/10.1200/JCO.2004.08.143 (2004).

4. Berthold, F. et al. Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial. Lancet Oncol 6, 649–658, https://doi.org/10.1016/S1470-2045(05)70291-6 (2005).

5. Yu, A. L. et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. The New England journal of medicine 363, 1324–1334, https://doi.org/10.1056/NEJMoa0911123 (2010).

Cited by 72 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. US Food and Drug Administration Approval Summary: Eflornithine for High-Risk Neuroblastoma After Prior Multiagent, Multimodality Therapy;Journal of Clinical Oncology;2024-09-01

2. The impact of thermophysical properties on eflornithine drug solute in acetone and ethyl acetate solvent interactions at varying concentrations and temperatures;BMC Chemistry;2024-08-16

3. Increased hepatic putrescine levels as a new potential factor related to the progression of metabolic dysfunction‐associated steatotic liver disease;The Journal of Pathology;2024-07-18

4. Visible-Light-Induced Hydrodifluoromethylation of Unactivated Alkenes with Difluoroacetic Anhydride;The Journal of Organic Chemistry;2024-06-07

5. Eflornithine for treatment of high-risk neuroblastoma;Trends in Pharmacological Sciences;2024-06